GlassScriptPhysician profile
Bashir Al Kaddoumi
NPI 1194996702
$19,589.65
in general payments reported to CMS, 2019-2025
30 companies · $54.96 in 2025
The $54.96 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $658 · 2021: $650 · 2022: $1,777 · 2023: $368 · 2024: $1,189 · 2025: $54.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $949 · Food and Beverage: $663.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $949.36 |
| Food and Beverage | $662.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $14,102.56 | 2019-2022 | |
| Boston Scientific Corporation | $1,098.62 | 2023-2024 | Versacross Access Solution, Varithena Administration Pack, Bodyguardian |
| Inari Medical, INC. | $947.96 | 2022 | |
| Biotronik INC. | $738.02 | 2019-2022 | |
| Amgen INC. | $548.95 | 2019-2024 | Repatha |
| Abbott Laboratories | $406.94 | 2019-2024 | Jot Dx, Merlin@Home |
| Astrazeneca Pharmaceuticals LP | $246.91 | 2019-2024 | Farxiga |
| Bard Peripheral Vascular, INC. | $238.90 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $221.59 | 2021-2023 | Verquvo |
| Novartis Pharmaceuticals Corporation | $143.13 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $115.30 | 2019-2021 | |
| Medtronic, INC. | $105.40 | 2022-2024 | Micra |
| Cardiovascular Systems INC. | $90.39 | 2019 | |
| Heartflow, INC. | $77.86 | 2019-2024 | Ffrct |
| Medtronic Vascular, INC. | $71.80 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $47.11 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $41.11 | 2019-2022 | |
| Irhythm Technologies, INC. | $40.97 | 2023 | Zio Xt Patch |
| Arbor Pharmaceuticals, INC. | $37.69 | 2021 | |
| Angiodynamics, INC. | $35.35 | 2020 | |
| Medicomp INC | $30.20 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.57 | 2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $25.39 | 2025 | Camzyos |
| Esperion Therapeutics, INC. | $24.30 | 2021 | |
| Tactile Systems Technology INC | $23.95 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $22.76 | 2023 | Arcalyst |
| Edwards Lifesciences Corporation | $22.22 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Amarin Pharma, INC. | $20.93 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $20.40 | 2019 | |
| Venclose INC. | $13.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bashir Al Kaddoumi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.